111 related articles for article (PubMed ID: 15247985)
21. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
22. Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay.
De Witte H; Sweep F; Brünner N; Heuvel J; Beex L; Grebenschikov N; Benraad T
Int J Cancer; 1998 Jul; 77(2):236-42. PubMed ID: 9650559
[TBL] [Abstract][Full Text] [Related]
23. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
[TBL] [Abstract][Full Text] [Related]
24. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
Zemzoum I; Kates RE; Ross JS; Dettmar P; Dutta M; Henrichs C; Yurdseven S; Höfler H; Kiechle M; Schmitt M; Harbeck N
J Clin Oncol; 2003 Mar; 21(6):1022-8. PubMed ID: 12637466
[TBL] [Abstract][Full Text] [Related]
25. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.
Sweep CG; Geurts-Moespot J; Grebenschikov N; de Witte JH; Heuvel JJ; Schmitt M; Duffy MJ; Jänicke F; Kramer MD; Foekens JA; Brünner N; Brugal G; Pedersen AN; Benraad TJ
Br J Cancer; 1998 Dec; 78(11):1434-41. PubMed ID: 9836475
[TBL] [Abstract][Full Text] [Related]
26. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Shariat SF; Monoski MA; Andrews B; Wheeler TM; Lerner SP; Slawin KM
Urology; 2003 May; 61(5):1053-8. PubMed ID: 12736046
[TBL] [Abstract][Full Text] [Related]
27. Circulating Her-2/neu extracellular domain in breast cancer patients-correlation with prognosis and clinicopathological parameters including steroid receptor, Her-2/neu receptor coexpression.
Barić M; Kulić A; Sirotković-Skerlev M; Dedić Plavetić N; Vidović M; Horvatić-Herceg G; Vrbanec D
Pathol Oncol Res; 2015 Jul; 21(3):589-95. PubMed ID: 25367073
[TBL] [Abstract][Full Text] [Related]
28. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
De Cremoux P; Grandin L; Diéras V; Savignoni A; Degeorges A; Salmon R; Bollet MA; Reyal F; Sigal-Zafrani B; Vincent-Salomon A; Sastre-Garau X; Magdelénat H; Mignot L; Fourquet A;
Anticancer Res; 2009 May; 29(5):1475-82. PubMed ID: 19443353
[TBL] [Abstract][Full Text] [Related]
29. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Kolk A; Pautke C; Horch HH
J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520
[TBL] [Abstract][Full Text] [Related]
30. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
31. Downregulation of Extracellular Matrix Metalloproteinase Inducer by scFv-M6-1B9 Intrabody Suppresses Cervical Cancer Invasion Through Inhibition of Urokinase-Type Plasminogen Activator.
Panich T; Tragoolpua K; Pata S; Tayapiwatana C; Intasai N
Cancer Biother Radiopharm; 2017 Feb; 32(1):1-8. PubMed ID: 28118037
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
33. Genetic polymorphism of urokinase-type plasminogen activator is interacting with plasminogen activator inhibitor-1 to raise risk of cervical neoplasia.
Tee YT; Wang PH; Tsai HT; Lin LY; Lin HT; Yang SF; Hsieh YH; Ying TH
J Surg Oncol; 2012 Aug; 106(2):204-8. PubMed ID: 22354580
[TBL] [Abstract][Full Text] [Related]
34. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.
Cantero D; Friess H; Deflorin J; Zimmermann A; Bründler MA; Riesle E; Korc M; Büchler MW
Br J Cancer; 1997; 75(3):388-95. PubMed ID: 9020484
[TBL] [Abstract][Full Text] [Related]
35. HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.
Harbeck N; Ross JS; Yurdseven S; Dettmar P; Pölcher M; Kuhn W; Ulm K; Graeff H; Schmitt M
Int J Oncol; 1999 Apr; 14(4):663-71. PubMed ID: 10087312
[TBL] [Abstract][Full Text] [Related]
36. Clinical relevance of urokinase-type plasminogen activator and its inhibitor type 1 (PAI-1) in squamous cell carcinoma of the uterine cervix.
Horn LC; Pippig S; Raptis G; Fischer U; Köhler U; Hentschel B; Martin R
Aust N Z J Obstet Gynaecol; 2002 Oct; 42(4):383-6. PubMed ID: 12403286
[TBL] [Abstract][Full Text] [Related]
37. Signalling networks associated with urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in breast cancer tissues: new insights from protein microarray analysis.
Wolff C; Malinowsky K; Berg D; Schragner K; Schuster T; Walch A; Bronger H; Höfler H; Becker KF
J Pathol; 2011 Jan; 223(1):54-63. PubMed ID: 21125664
[TBL] [Abstract][Full Text] [Related]
38. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
39. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression.
Baker EA; Bergin FG; Leaper DJ
Mol Pathol; 2000 Dec; 53(6):307-12. PubMed ID: 11193049
[TBL] [Abstract][Full Text] [Related]
40. Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy.
Bellone S; Palmieri M; Gokden M; Joshua J; Roman JJ; Pecorelli S; Cannon MJ; Santin AD
Gynecol Oncol; 2003 Oct; 91(1):231-40. PubMed ID: 14529687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]